Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Blepharitis - Overview
Blepharitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Blepharitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Blepharitis - Companies Involved in Therapeutics Development
Blepharitis - Drug Profiles
Blepharitis - Dormant Projects
Blepharitis - Product Development Milestones
Featured News & Press Releases
Feb 08, 2022: Tarsus to host eye care leaders webcast on unmet needs in demodex blepharitis and potential of TP-03
Feb 02, 2022: Tarsus Completes enrollment for the pivotal phase 3 Saturn-2 trial of TP-03 to treat demodex blepharitis and secures $175 million credit facility
Nov 30, 2021: Nicox’s positive post hoc results from NCX 4251 phase 2b Mississippi trial suggest path forward in dry eye disease
Nov 17, 2021: Nicox is granted patent for blepharitis product candidate NCX 4251 in Europe
Nov 04, 2021: Tarsus Pharmaceuticals, presents data from two pioneering studies on the prevalence and impact of Demodex Blepharitis at the American Academy of Optometry 2021 Annual Meeting
Aug 31, 2021: AxeroVision announces phase 2 results for AXR-270 for treatment of dry eye disease associated with MGD
Jul 24, 2021: Tarsus Pharmaceuticals presents new Saturn-1 pivotal trial data and Titan real-world prevalence study results at ASCRS 2021
Jul 02, 2021: Nicox announces last patient completed NCX 4251 Mississippi phase 2b blepharitis trial
Jun 21, 2021: Tarsus Pharmaceuticals announces positive results of Saturn-1 pivotal trial evaluating TP-03 for the treatment of demodex blepharitis
Jun 18, 2021: Tarsus Pharmaceuticals schedules conference call and webcast to announce saturn-1 phase 2b/3 pivotal trial results for TP-03 for the treatment of Demodex Blepharitis
Jun 01, 2021: Nicox’s completes pre-defined enrollment of NCX 4251 Mississippi phase 2b Blepharitis trial
May 06, 2021: Tarsus Pharmaceuticals initiates Saturn-2, second pivotal phase 3 trial evaluating the safety and efficacy of TP-03 for the treatment of Demodex blepharitis
May 03, 2021: Tarsus Pharmaceuticals presents results of pioneering Atlas study at ARVO 2021 annual meeting demonstrating the functiol and psychosocial impact of demodex blepharitis
Apr 23, 2021: Nicox’s NCX 4251 Mississippi Phase 2b blepharitis trial reaches 50% enrollment
Mar 17, 2021: Hovione completes its Phase 2 clinical trial of the first minocycline ophthalmic showing promise in Dry Eye Disease associated with Inflamed Meibomian Gland Dysfunction
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Blepharitis, 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Blepharitis, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Blepharitis - Pipeline by Aerie Pharmaceuticals Inc, 2022
Blepharitis - Pipeline by Aperta Biosciences LLC, 2022
Blepharitis - Pipeline by AxeroVision Inc, 2022
Blepharitis - Pipeline by Azura Ophthalmics Pty Ltd, 2022
Blepharitis - Pipeline by Formosa Pharmaceuticals Inc, 2022
Blepharitis - Pipeline by Hovione FarmaCiencia SA, 2022
Blepharitis - Pipeline by Merck & Co Inc, 2022
Blepharitis - Pipeline by NicOx SA, 2022
Blepharitis - Pipeline by NTC srl, 2022
Blepharitis - Pipeline by Premark Pharma GmbH, 2022
Blepharitis - Pipeline by Quorum Innovations LLC, 2022
Blepharitis - Pipeline by Santen Pharmaceutical Co Ltd, 2022
Blepharitis - Pipeline by Sol-Gel Technologies Ltd, 2022
Blepharitis - Pipeline by Tarsus Pharmaceuticals Inc, 2022
Blepharitis - Dormant Projects, 2022